Our target selection strategy centers around leveraging our discovery engine to address disease targets with significant unmet patient needs that cannot be adequately met by conventional treatments. We are initially focused on targets with strong genetic and clinical validation, and we believe that oral peptide therapies offer a more effective means of unlocking the desired biology, improving clinical outcomes, and increasing patient convenience.
We have assembled a range of integrated approaches to accelerate the discovery and development of oral peptide-based therapies. Our core platform not only aids in the rapid screening of various libraries but also enables a deeper understanding of crucial molecular interactions, that is required to optimize parameters such as potency, stability, gut permeability, half-life, and metabolism.
Our proprietary light-directed peptide synthesis platform can generate >100 million individual peptidomimetic compounds overnight, each with a unique chemical composition selected from our expanding collection of >2000 natural and non-natural amino acids.
Our hit discovery combines our proprietary light-directed chemical synthesis technology with display technologies. Our library molecular structures range from from 3 to 20 amino acids and beyond, and not limited to any particular scaffold. Scaffolds include cyclic, head-to-tail, thioether, disulfide, bicyclic or tricyclic peptidomimetic compounds, linear, helices, beta sheets, lariats, and many more.
We individually assay each peptide for its target binding, biofluid stability, solubility, and much more. Our massive datasets identify crucial interactions facilitating data-driven discoveries. Ultimately, this approach guides the selection of optimal leads for preclinical development.
Our preclinical studies deepen our understanding of the relationships between targets, drug properties, and oral bioavailability through comprehensive in vitro and in vivo pharmacokinetic/pharmacodynamic and efficacy studies of our oral peptides across multiple animal models.
Our pipeline at Nimble Therapeutics is strategically focused on addressing diseases with significant patient need and where we believe oral peptides can deliver enhanced benefits relative to existing treatments. This targeted approach enables us to create innovative solutions that improve patients’ lives.
We collaborate with pharmaceutical, biotechnology companies, and academic institutions to combine their expertise with ours.
This strategic partnership enables us to broaden the scope of our programs and develop pioneering therapies that can have a profound impact on the lives of millions.
Our research efforts are centered around leveraging our discovery engine to pinpoint molecules that effectively block critical protein targets associated with immune-mediated disorders. This approach will enable us to create novel oral treatments that can make a meaningful difference in patient outcomes.
Nimble Therapeutics’ proprietary chemical language enables rapid and efficient implementation of design concepts into a set of complete instructions for fully automated, massively parallel library synthesis. These custom-built tools are deeply integrated with our high-precision, fully automated, light-directed chemical synthesis platform. Together, this enables Nimble to design libraries unique to each target and encompassing a chemical space bounded only by imagination.
Explore some design concepts & core implementation of our platform.
Inspired by traditional solid-phase synthesis, Nimble Therapeutics’ proprietary instrumentation represents a sophisticated integration of photolithography, precision optics, fluidics, and automation. Our platform enables exquisite combinatorial synthesis of tailor-made libraries in a matter of hours from up to hundreds of different monomers, in linear cyclic and branched conformations.
Fragment Based Discovery
Protein-Protein Disruptor Discovery
Rapid Phage Single-Step Selection & Step-Wise Array Optimization
Small Branched & Cyclic Peptide Discovery Libraries
Scaffolded alpha helical, beta hairpins Discovery Libraries
Nimble Therapeutics’ veteran team has developed and implemented biological assays for massively parallel screening and optimization of peptides towards molecules with pharmaceutically relevant properties. Our ability to explore and interrogate multiple parameters of molecules in parallel guides downstream modifications harmonized with both the target location and disease.
Our advanced and proprietary analytical pipeline, integrating bioinformatics, chemoinformatics, and machine learning, is engineered from the ground up to transform massive empirical data sets into actionable insights. This purpose-built informatics platform is applied to both de novo library design and subsequent characterization of the resulting empirical data. This process informs creation of the next bespoke library, and fuels a rapid, highly iterative approach to engineering peptides optimized for multiple characteristics in parallel.
OPTIONAL Related Documentation Title Here View PDF
